Primary Pediatric Hypertension Workshop: Epidemiology and Treatment Gaps
Date: Monday, September 25, 2017
Time: 8:15 a.m. to 4:30 p.m.
Location: 6710B Rockledge Drive, 1st Floor Conference Rooms (1425/1427) Bethesda, MD 20817
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH) in collaboration with the U.S. Food and Drug Administration (FDA) and National Heart Lung and Blood Institute (NHLBI), NIH welcomes you to a workshop titled “Primary Pediatric Hypertension Workshop: Epidemiology and Treatment Gaps”.
The goal of the workshop is to:
- identify research priorities for the improved diagnosis and treatment of primary hypertension in the pediatric population.
The purpose of this one-day workshop is to:
- discuss the current state of hypertension epidemiology, pathophysiology, diagnosis, and treatment in the pediatric population.
Leading experts in the field have been invited to identify research priorities for the improved diagnosis and treatment of hypertension in the pediatric population.
The meeting will bring together representatives from the National Institutes of Health, the U.S. Food and Drug Administration, academia, and industry to discuss the potential growing rates of undiagnosed hypertension in children related to the rising rates of obesity in this country.
This workshop is very timely. The American Academy of Pediatrics issued their new pediatric hypertension clinical practice guideline on August 21, 2017. In announcing their new guideline, the AAP stated that:
“Pediatric hypertension, occurring in 2%–5% of all pediatric patients, is one of the top five chronic diseases in children and adolescents. The diagnosis is missed in up to 75% of pediatric patients in primary care settings, and appropriate medication initiation occurs much less frequently than is indicated, according to current guidelines.”
Appropriate detection and treatment of primary pediatric hypertension will require an extensive knowledge of the epidemiology and current diagnostic criteria for primary pediatric hypertension (Module 1), the pathophysiology of primary pediatric hypertension (Module 2), and of the current knowledge of and future directions in the treatment of primary pediatric hypertension (Module 3).
--]){kind=small}
Webcast: Specific information will be provided with registration.
For questions regarding the workshop, please contact:
Perdita Taylor-Zapata, M.D., Medical Officer
Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)
taylorpe@mail.nih.gov
Gilbert J. Burckart, Pharm.D.
Associate Director for Pediatrics
Office of Clinical Pharmacology
10903 New Hampshire Ave.
Silver Spring, MD 20993
301-796-2065
gilbert.burckart@fda.hhs.gov